Clinical Trial

Imaging of Solid Tumors Using FAP-2286

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-11-03; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2020-12-14
Trial Details
NCT Number NCT04621435
Lead Sponsor Thomas Hope
Collaborators: Society of Abdominal Radiology
Conditions Solid Tumors, Adult, Metastatic Cancer
Enrollment 191 participants
Start Date 2020-12-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04